Skip to main content
. 2018 Feb 12;98(4):1152–1158. doi: 10.4269/ajtmh.17-0637

Table 1.

Baseline demographic and clinical data, inflammatory, translocation, and other blood markers

Variable Rifaximin group Non-rifaximin group
Age (years) 42 (30, 52) 38 (31,43)
Gender Females 24 Females 16
Males 20 Males 25
BMI (kg/m2) 21.6 (19.9, 23.2) 21.5 (20.3, 23.8)
No. of cases with history of hematemesis Yes 27 Yes 26
No 17 No 15
Pulse rate (beats/minute) 76 (66, 82) 70 (64, 76)
Hb (g/dL) 7.5 (6.2, 11.3) 9.2 (6.6, 11.0)
WCC (×109/L) 2.7 (1.6, 3.5) 1.8 (1.6, 3.0)
PLT (×109/L) 49 (31, 78) 44 (24, 64)
MCV (fl) 80 (67, 87) 79 (70, 83)
MPV (mm) 12.7 (11.2, 13.9) 12.1 (10.8, 13.6)
16S rRNA copies/µL 129 (23, 499) 51 (19, 112)
LPS (ng/mL) 74 (38, 157) 154 (45, 649)
LBP (ng/mL) 27 (23, 30) 43 (38, 50)
TNFR1 (ng/mL) 1,443 (1,232, 1,911) 1,495 (1,238, 1,657)
sCD14 (ng/mL) 2,402 (1,930, 2,798) 1,487 (1,299, 1,964)
Hyaluronan (ng/mL) 125 (57, 189) 102 (71, 176)

BMI = body mass index; Hb = hemoglobin; LBP = lipopolysaccharide-binding protein; LPS = lipopolysaccharide; MCV = mean cell volume; MPV = main portal vein diameter; PLT = platelets; sCD14 = soluble cluster of differentiation 14; WCC = white cell count; TNFR1 = tumor necrosis factor receptor 1.

All parameters are represented as median with interquartile range in parenthesis.